Yan Si

Dr. Yan Si


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2025 in Oncology Letters
Verified
Journal Article
Open access
PDF file
ZLZhuozheng Li
Zhuozheng Li
NWNuofan Wang
Nuofan Wang
XLXiao Li
Xiao Li
YXYongfang Xie
Yongfang Xie
ZDZemin Dou
Zemin Dou
GWGuohui Wang
Guohui Wang
Thyroid cancer, a prevalent endocrine malignancy with rising global incidence, encompasses four primary subtypes: Papillary (PTC), follicular (FTC), medullary (MTC) and anaplastic thyroid carcinoma (ATC). PTC, accounting for 85‑90% of cases, is primarily driven by BRAF V600E mutations alongside dysregulated non‑coding RNAs, such as long non‑coding RNA metastasis‑associated lung adenocarcinoma transcript 1 and microRNA (miR)‑1270. These alterations collectively activate MAPK signaling, promoting tumorigenesis. Furthermore, PTC exhibits metabolic reprogramming characterized by dysregulated glucose and lipid metabolism, where tumor suppressors, including family with sequence similarity 111 member B and fat mass and obesity‑associated genes, constrain glycolytic flux. FTC, characterized by Ras mutations, exhibits enhanced lipid metabolism and PI3K/AKT pathway activation. Methyltransferase‑like protein 16 and sclerostin domain‑containing protein 1 have been highlighted as regulators of FTC progression. MTC, associated with rearranged during transfection (RET) proto‑oncogene mutations, demonstrates programmed cell death protein‑1/programmed death ligand‑1 pathway involvement, which offers potential immunotherapy targets. ATC, the most aggressive subtype, is characterized by recurrent genetic alterations such as telomerase reverse transcriptase promoter and tumor protein p53 mutations, cAMP‑responsive element‑binding protein 3‑like 1‑driven activation of cancer‑associated fibroblasts and hematological and neurological expressed 1‑stathmin 1 signaling‑mediated invasiveness. Recent diagnostic innovations encompass serum biomarkers, such as stanniocalcin‑1, microRNA signatures (including miR‑26b‑5p) for PTC and MTC detection, radiomics‑based differentiation of ATC from other subtypes and optical imaging techniques for precision diagnosis. Molecularly targeted therapies constitute the cornerstone of current strategies, with vemurafenib inhibiting BRAF/MEK in PTC, sorafenib acting as a multikinase suppressor in FTC, vandetanib blocking RET in MTC and berberine‑doxorubicin combinations overcoming chemoresistance in ATC. Metabolic interventions, including metformin for glucose modulation in PTC and novel delivery systems such as micelle‑encapsulated AB3 for MTC, demonstrate translational potential. The present review summarizes molecular mechanisms, diagnostic tools and emerging therapies while emphasizing the necessity of subtype‑specific approaches to improve clinical outcomes in thyroid oncology.

18 March 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
XWXiaoting Wang
Xiaoting Wang
YSYan Si
Yan Si
JCJingsheng Cai
Jingsheng Cai
HLHui Lu
Hui Lu
HTHouchao Tong
Houchao Tong
MSMeiping Shen
Meiping Shen

8 November 2025 in Seminars in Oncology
Verified
Journal Article
Closed access
LZLijun Zhang
Lijun Zhang
CLChengyuan Li
Chengyuan Li
JZJianing Zhou
Jianing Zhou
XZXiang Zhang
Xiang Zhang
HFHaisheng Fang
Haisheng Fang
YSYan Si
Yan Si